• Profile

AJM300 (carotegrast methyl), an oral alpha4-integrin antagonist, for patients with moderate ulcerative colitis: a phase 3 trial

The Lancet: Gastroenterology & Hepatology Apr 27, 2022

Why this study matters

The long-term management of UC is often complicated by an inadequate response to mesalazine and treatment failure with TNFis.   Effective and safe oral immune cell trafficking inhibitors, such as AJM300, are accepted and well-tolerated by patients and have low immunogenicity.

Study design

This phase 3 trial was conducted at 82 hospitals and clinics in Japan.  Two hundred three patients with a Mayo Clinic score of 6-10, an endoscopic score > 2, a rectal bleeding subscore > 1, and an inadequate or lack of response to mesalazine were enrolled and received AJM300 or placebo for 8 weeks. 

Results and conclusion

A clinical response occurred by week 8 in 46% and 21% of the patients who received AJM300 and placebo, respectively.  The incidence of adverse events, the most frequent of which was nasopharyngitis, was similar in both groups of patients and considered mild-to-moderate in severity.

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen